0001209191-22-050704.txt : 20220920
0001209191-22-050704.hdr.sgml : 20220920
20220920160833
ACCESSION NUMBER: 0001209191-22-050704
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220916
FILED AS OF DATE: 20220920
DATE AS OF CHANGE: 20220920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jarrett Jennifer
CENTRAL INDEX KEY: 0001671311
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38419
FILM NUMBER: 221253721
MAIL ADDRESS:
STREET 1: C/O MEDIVATION, INC.
STREET 2: 525 MARKET ST., 36TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcus Biosciences, Inc.
CENTRAL INDEX KEY: 0001724521
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473898435
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3928 POINT EDEN WAY
CITY: HAYWARD
STATE: CA
ZIP: 94545
BUSINESS PHONE: (510) 694-6200
MAIL ADDRESS:
STREET 1: 3928 POINT EDEN WAY
CITY: HAYWARD
STATE: CA
ZIP: 94545
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-16
0
0001724521
Arcus Biosciences, Inc.
RCUS
0001671311
Jarrett Jennifer
C/O ARCUS BIOSCIENCES, INC.
3928 POINT EDEN WAY
HAYWARD
CA
94545
1
1
0
0
Chief Operating Officer
Common Stock
2022-09-16
4
S
0
12677
26.28
D
130942
D
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.89 to $26.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Carolyn Tang, Attorney-in-Fact
2022-09-20